(Q33372859)

26 July 2017

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma (English)

1 reference

26 July 2017

0 references

1 reference

hepatocellular carcinoma

1 reference

Sheng-Nan Lu

1

1 reference

26 July 2017

Jing-Houng Wang

2

1 reference

26 July 2017

Shiann-Long Liu

3

1 reference

26 July 2017

Chao-Hung Hung

4

1 reference

26 July 2017

Chien-Hung Chen

5

1 reference

26 July 2017

Hung-Da Tung

6

1 reference

26 July 2017

Tsung-Ming Chen

7

1 reference

26 July 2017

Wu-Shiung Huang

8

1 reference

26 July 2017

Chuan-Mo Lee

9

1 reference

26 July 2017

Chia-Cheng Chen

10

1 reference

26 July 2017

Chi-Sin Changchien

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

26 July 2017

1 reference

26 July 2017

107

1 reference

26 July 2017

9

1 reference

26 July 2017

2212-2222

1 reference

Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Hepatitis B and C viruses in the development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan--a dried blood spot method.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Mass screening for hepatocellular carcinoma: Experience in Hokkaido, Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

The meaning and use of the area under a receiver operating characteristic (ROC) curve

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

A method of comparing the areas under receiver operating characteristic curves derived from the same cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22242

1 reference

7 January 2021

The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Analysis of background factors and evaluation of a population at high risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Thrombopoietin-producing hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22242

7 January 2021

Identifiers

DOI

10.1002/CNCR.22242

1 reference

26 July 2017

1 reference